期刊文献+

多发性骨髓瘤异常miRNAs表达的研究进展 被引量:2

Advances of Aberrant miRNAs Expression in Multiple Myeloma
下载PDF
导出
摘要 miRNAs(microRNAs)是一类短小的非编码RNAs,通过调节基因表达的转录水平,影响细胞周期进程并起关键作用,参与细胞的增殖、代谢、凋亡与分化。miRNAs的异常表达促进肿瘤发生,包括多发性骨髓瘤(MM)。本文就miRNAs在MM中的发病机制、诊断、治疗及预后评估的最新研究进展作一综述。 miRNAs(microRNAs) are short non-coding RNAs that play critical roles in numerous cellular processes through post-transcriptional regulating functions, and participate in the regulation of cell proliferation, metabolism, apoptosis and differentiation. The dysregulation of miRNA expression contributes to tumorigenesis, including multiple myeloma(MM). In this review we summarize the current knowledge on roles of miRNAs in the pathogenesis, diagnosis, treatment and prognosis of MM.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2014年第10期1139-1143,共5页 Cancer Research on Prevention and Treatment
关键词 miRNAs(MicroRNAs) 多发性骨髓瘤 表观遗传学 发病机制 诊断 microRNAs Multiple myeloma(MM) Epigenetics Pathogenesis Diagnosis
  • 相关文献

参考文献4

二级参考文献32

  • 1Kyle RA,Rajkumar SV. Multiple myelomB. Blood,2008,111 2962-2972.
  • 2Bleau AM, I-Iambardzumyan D, Ozawa T, et al. PTEN/PDK/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell, 2009,4 : 226-235.
  • 3Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and mieroRNAs. Drug Resist Updat, 2007, 10: 59-67.
  • 4Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res ,2009,69 : 2996-3003.
  • 5Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL ~ , Aft-null lymphoblastic leukemia. Genes Dev,2007,21: 2283-2287.
  • 6Meads MB, Hazlehurst LA, Dalton WS. The bone man~w microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res,2008,14 : 2519-2526.
  • 7Podar K, Chauhan D, Anderson KC. Bone microenvironment and the identification of new targets for myeloma therapy. Leukemia, 2009,23 : 10-24.
  • 8Roorda BD, ter Elst A, Kamps WA, et al. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived ceils to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol,2009,69: 187-198.
  • 9Bisping G, Wenning D, Kropff M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t ( 4 ; 14 ) myeloma. Clin Cancer Res, 2009.15:520-531.
  • 10Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma~ Int J Hematol, 2011, 94:334-343.

共引文献25

同被引文献8

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部